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Summary 
Using sialyl Lewis  x (SLX) oligosaccharides derived from fucosyl transferase-expressing cells or 
generated synthetically, the ability of these compounds to protect against acute lung damage 
after deposition of immunoglobulin (Ig)G or IgA immune complexes has been determined. The 
synthetic compounds were tetra- and pentasaccharide  derivates  of SLX as well as the nonfucosylated 
forms of SLX as controls. In the IgG immune complex modal of lung injury, which is E-selectin 
dependent, SLX preparations provided dose-dependent protective effects, as assessed by changes 
in lung vascular permeability and hemorrhage. Protective effects were associated with diminished 
tissue accumulation of neutrophils  in lungs (as assessed by myeloperoxidase). Morphological 
assessment revealed  reduced physical  contact of neutrophils with the pulmonary vascular endothelium 
and reduced tissue accumulation of neutrophils. In the model of IgA immune complex-induced 
lung injury,  which does not involve participation  of neutrophils  and is independent of the 
requirement for E-selectin, SLX preparations were not protective. These data suggest that,  in 
neutrophil-mediated and E-sdectin-dependent  lung injury, SLX preparations provide significant, 
protective effects against inflammatory vascular injury. The ability to achieve antiinflammatory 
outcomes in vivo with appropriate oligosaccharides suggests a new approach to the blocking 
of acute inflammatory responses. 
T 
he selectin family of leukocyte-promoting molecules  con- 
sists of three structurally homologous  glycoproteins con- 
taining, in the extracellular  region, a calcium-dependent lectin 
binding domain, an epidermal growth factor (EGF) region, 
and a series of repeating complement-binding-like  domains 
(1-7). Endothelial  cells  can be stimuhted to synthesize  E-sdectin 
(endothelial leukocyte adhesion molecule type 1 [ELAM-1]), 
resulting in its induced expression on the cell membrane in 
2-4 h (3). On the other hand, activation of endothelial cells 
or platelets by thrombin or histamine leads to rapid expres- 
sion on the cell membrane of P-selectin  (GMP-140, PADGEM), 
which is translocated from storage granules. Both E- and P- 
sdectin react with the sialyl Lewis  ~ (SLX)  1 oligosaccharide 
and chemically related oligosaccharides  (8-11). SLX expressed 
by neutrophils appears to be important in their adhesion to 
activated endothelial cells via E-selectin pathways (8). Engage- 
ment of selectin pathways is considered to be the first critical 
adhesion  pathway  that  is  associated with  the  rolling 
phenomenon of neutrophils along the endothelial surfaces 
1  Abbreviations used in thisfmper: DSA, Datura straraoniura  agglutin; MPO, 
myeloperoxidase;  SLX, sialyl Lewis  x. 
(12-14). Sdectin engagement appears to be sequentially fol- 
lowed by participation of 82 integrin molecules on neutro- 
phils, together with their "counter-receptor"  on the endothelial 
cells, intercellular adhesion molecules 1 and 2 (ICAM-1 and 
-2), after which firm attachment of leukocytes to the en- 
dothelial surface and transmigration of neutrophils to extravas- 
cular sites occur (15). 
Using blocking mAbs, we have recently demonstrated that 
E-sdectin is critical for the development of acute lung injury 
in rats after deposition of IgG immune complexes (16). In 
this model, lung vascular injury is critically dependent upon 
activation of neutrophils, their physical contact with and ad- 
herence to the endothelium, and generation of toxic oxygen 
products  (17). In the current studies we have infused SLX 
oligosaccharides  intravenously and have demonstrated signifi- 
cant protective effects  against lung injury in the IgG immune 
complex-induced model of E-selectin-dependent lung injury. 
These protective effects were correlated with reduced adher- 
ence of neutrophils to the endothelium  and diminished tissue 
accumuhtion of neutrophils. In contrast, in IgA immune com- 
plex-induced lung injury, which is independent of the re- 
quirements for E-selectin and neutrophils, SLX preparations 
623  J. Exp.  Med. ￿9  The Rockefeller  University Press ￿9 0022-1007/93/08/0623/09  $2.00 
Volume  178  August 1993  623-631 were not protective. These findings suggest that SLX oligosac- 
charides may be a useful approach in blocking injury in the 
acute lung inflammation that is E-selectin dependent. 
Materials and Methods 
Reagents.  Except where mentioned, all reagents were purchased 
from Sigma Chemical Co. (St. Louis, MO). 
Animals.  Adult male (300-gm)  specific pathogen-free Long- 
Evans rats purchased from Charles River Labs (Portage, MI) were 
used in the studies. 
Preparation of GIFopeptides.  Cultured transfected Chinese ham- 
ster ovary (CLIO) cell lines served as a source for glycopeptides. 
SLX-positive glycopeptides  were prepared  from an SLX-positive 
ClIO cell line transfected with a human c~(1,3/1,4)fucosyltransferase 
cDNA (CHO-FT cells) (11). Control, SLX-negative glycopeptides 
were prepared from an SLX-negative Chinese hamster ovary cell 
line transfected  with a control vector without a cDNA insert 
(CHO-V cells). Conditions for growing these cell lines have been 
described elsewhere (11). 
For  preparation  of [3H]galactose-labeled  glycopeptides  from 
CHO-FT cells for oligosaccharide structural analysis,  CHO-FT cells 
(plated at a density of 5  x  106 cells per 150-ram dish) were la- 
beled for 24 h in c~-MEM containing 10% FCS, 1% glucose, and 
250  #Ci  [3H]galactose  (25.5  Ci/mmol;  Amersham  Corp., 
Arlington Heights, IL). After labeling,  the cell monolayers were 
washed and the cells were harvested and processed exactly as noted 
above for the preparation of glycopeptides. The glycopeptides were 
fractionated by gel chromatography and were subjected to struc- 
tural analysis by serial lectin affinity chromatography, exo- and en- 
doglycosidase digestions,  and methylation analyses. An aliquot of 
each expanded cell line was subjected to flow cytometry analysis 
at the time of harvest to ensure that the appropriate  cell surface 
glycoconjugate phenotypes were present.  The CHO-FT cells re- 
mained uniformly SLX positive, whereas  the CHO-V cells were 
SLX negative,  as expected.  In addition, two confluent 150-mm 
dishes of each cell line were radiolabeled with [14C]galactose (61 
mCi/mmol; Amersham Corp.) to allow detection by scintillation 
counting of glycopeptides that were chromatographically isolated. 
Cells were radiolabeled by incubating the monolayers for 20 h in 
media containing [14C]galactose (5.5  x  10  ~ cpm). 
Confluent CHO-FT or CHO-V cell monolayers were removed 
from the plates with PBS containing 3 mM EDTA (11). The radio- 
labeled cell monolayers were harvested in parallel with the nonla- 
beled monolayers and pooled with the nonlabeled cells. The cells 
were then pelleted and subjected to a series of solvent extractions 
before pronase digestion, as described previously (18-20). Briefly, 
the cell pellets were extract three times with chloroform/meth- 
anol (2:1), once with methanol, and then twice with water. The 
pellet remaining after the last extraction was resuspended in 100 
mM Tris, pH 7.4,  1 mM CaC12. Pronase (pronase E, type XIV) 
was added to a final concentration of 25 mg/ml, and the mixture 
was digested for 16 h at 37~  The mixture was then subjected 
to two additional periods (16 h) of  digestion with pronase, at which 
time the mixture was supplemented  with additional pronase (3.3 
mg/ml of pronase added). After the last digestion, insoluble mate- 
rial (,'ol.5-ml vol per 15-ml digestion) was removed by centrifuga- 
tion, and the supematant fluid was incubated at 100~  for 5 min. 
The supernatant fluid was then filtered through a 0.4-/~m cellulose 
acetate filter, frozen, thawed, and filtered again. The solution was 
subsequently subjected to gel filtration chromatography through 
a  Sephadex  G-25  column  (2.5  x  20  cm)  equilibrated  in  5% 
isopropanol in water, at a rate of 1 ml/min, with 100-/A fractions 
being collected. Each aliquot was subjected to scintillation counting. 
Fractions within the peak corresponding to the excluded volume 
(glycopeptides) were pooled, lyophilized, and were resuspended in 
2.5 ml of water. The protein concentration of the pooled glycopep- 
tides was determined using the anthrone method (21). The SLX- 
positive preparation was adjusted to a concentration of 1.39 mg/ml 
(reducing sugar concentration)  with a protein concentration of 270 
/zg/ml. The control, SLX-negative material was resuspended at a 
concentration of 1.59 mg/ml with a protein concentration of 290 
/zg/ml. These labeled glycopeptides were analyzed after fraction- 
ated through Con A-Sepharose, followed by Datura stramonium ag- 
glutin (DSA)-agarose chromatography (18). The glycoproteins that 
did not bind to these two columns represent  N-glycans enriched 
with SLX structures.  In addition, glycopeptides that were bound 
to DSA-agarose were also analyzed since they represent N-glycans 
with N-acetyllactosamine  repeats. 
To estimate the amount of terminal structures in the glycopep- 
tides, the glycopeptide  fractions were sequentially digested with 
diplococcal  3-galactosidase  and diplococcal  3-N-acetylhexosaminidase 
(Exp.  1).  Another portion of glycopeptides  were digested with 
oel,3/1,4-spedfic  fucosidase (19) followed by ~-galactosidase and 
/J-N-acetylglucosaminidase  (Exp. 2). In separate experiments,  the 
glycopeptides were first digested with Newcastle disease virus neur- 
aminidase and asialo-glycopeptides were separately treated with ex- 
oglycosidases as described for intact glycopeptides (Exps. 3 and 4). 
The glycopeptides were subjected to Sephadex G-50 gel filtration 
before and after digestion, and the released galactose was deter- 
mined in relation to  the  total radioactivity recovered after  gel 
filtration. 
The amount of galactose released in Exps. 1 and 2 corresponded 
to the amount of GalB1,4GlcNAc and Gal~l,4(Fucoel,3)GlcNAc. 
The amount of galactose released in Exps. 3 and 4 corresponded 
to the amount of NeuNAe~2,3GalB1,4GlcNAc  and NeuNAc~2,3- 
GalB1,4(Fuc~-l,3)GlcNAc, respectively. This estimation is possible 
because the ed,3/4 fucosidase was found to barely hydrolyze the 
fucosidic linkage in the SLX structure, but hydrolysis readily occurs 
with GalB1,4(Fuccd,3)GlcNAc  (18) (see Table 1). 
74% of 3H-labeled glycopeptides from CHO-FT cells failed to 
bind to Con A-Sepharose and DSA-agarose. From these glyeopep- 
tides, 3.9, 2.0, 16.3, and 29.1% of the total radioactivity was enzy- 
matically released in Exps. 1, 2, 3, and 4, respectively. The results 
indicate these glycopeptides contain, 0.15, 0.08, 0.65, and 1.16 tool 
of GalB1,4G1cNAc, GalB1,4(Fuc~I,3)GIcNAc, NeuNAcax2,3Ga131, 
4GlcNAc, and NeuNAcoe2,3GalB1,4(FucoL1,3)GlcNAe per mole- 
cule of the glycopeptides, respectively. The results also indicate these 
glycopeptides contain, on average, 2 tool of N-acetyllactosamine 
repeats, since only 50% of the total radioactivity was removed by 
one cycle of the sequential enzyme digestion. The results obtained 
on DSA-bound glycopeptides (11.4% of the total radioactivity) were 
similarly calculated. 
Animal Models of lgG and IgA Immune Complex-induced Alveo- 
litis.  Rabbit polyclonal IgG rich in antibody to BSA (anti-BSA) 
was used in the first model. IgG was purchased  from Organon 
Technika  (Westchester,  PA).  Intraperitoneal  ketamine was  ad- 
ministered for anesthesia. 2.5 mg anti-BSA in a volume of 300/~1 
was intratracheally instilled via a small intratracheal catheter during 
inspiration after surgical exposure of the trachea.  Intravenous in- 
jection of 10 mg BSA together with trace amounts of nSI-BSA 
and SlCr-RBC,  as described  in detail  elsewhere  (16), was used. 
Rats were killed 4 h later and lung injury was quantitated by per- 
meability and hemorrhage measurements.  For induction of IgA 
immune complex-induced lung injury, murine myeloma IgA pro- 
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previously described (22). 1.2 mg IgA anti-DNP was instilled in- 
tratracbeaUy and 3.3 mg DNP-BSA injected intravenously  together 
with S1Cr-RBC and trace amounts of 1~I-BSA, as described above. 
As with the IgG immune complex model of lung injury, injury 
was measured  at 4 h and assessed  by increased  vascular  permeability 
and hemorrhage. As described above, protective interventions in- 
volved the intravenous  injection of oligosaccharides  at 2.5, 3.0, and 
3.5 h after initiation of IgA immune complex deposition in lung. 
When used in vivo, 400/zl of the CHO-FT preparation (and 
of the composition described in Table 1) was injected intravenously 
in three equally divided doses at 2, 2.5, and 3 h after deposition 
of IgG immune complexes. This schedule  for injections  was selected 
since it coincides with the time during which rapid expression of 
E-selectin occurs in the pulmonary vasculature  (16). This dose con- 
tained 556/zg carbohydrate and 108/~g  protein. Reference-positive 
controls received PBS or 400/~1 CHO-V preparation in a similar 
injection schedule. In the latter, the injected preparation contained 
636/zg carbohydrate and 116 #g protein. The purified SLX prepa- 
ration with reducing sugar (SLX-OH) as well as the tetrasaccha- 
ride and pentasaccharide  carbonyl derivatives  of SLX were prepared 
biosynthetically as described in a recent paper (23). When used, 
indicated doses of SLX(OH) or tetrasaccharide or oligosaccharide 
carbonyl derivative were also injected intravenously  at 2.5, 3.0, and 
3.5 h after initiation of the immune complex-induced  lung inflam- 
matory models of injury. 
Synthetic Oligosaccharides.  Synthetic derivatives of SLX and 
related nonfucosylated  analogues were prepared by combined  chem- 
ical and enzymatic synthesis (23, 24). Compounds used in this re- 
port included  reducing sugars, NeuAc~2,3GalB1,4GlcNeuFz  (SLN- 
OH) and NenAccc2,3GalB1,4(Fucc~l,3)GlcNAc  (SLX-OH); and 
glyeosides  NeuAc2, 3GaI~I,4(Fuc~I,3)GIcNAc-/~-0(CH2)COOCH3 
(SLX-tetra) and NeuAc~2,3Gal~l,4  (Fuc~I,3)GlcNAc~I,3Gal~- 
0-(CH2)sCOOCH3 (SLX-penta). 
Tissue Myeloperoxidase  (MI~) Activity.  To assess the use of tissue 
MPO activity as a measure of neutrophil influx, known numbers 
of glycogen-elicited rat peritoneal neutrophils were instilled into 
the airways of normal rat lungs, the tissue was homogenized and 
extracted, and standard  curves were produced  as previously  described 
(16). Lung samples obtained 4 h after deposition of immune com- 
plexes were homogenized with a polytron homogenizer (Techmar 
Co., Cincinnati, OH) using 6 ml of homogenization buffer (50 
mM phosphate, pH 6.0) and subjected to centrifugation (3,000 g; 
30 min at 4~  MPO activity in supernatant fluids was assayed 
by measuring the change in absorbance at 460 nm resulting from 
oxidation of o-dianisidine in the presence of H202. 
Mo~hologic Evaluation of Lungs and Skin.  Lungs were fixed in 
glutaraldehyde and embedded in epon and processed for light mi- 
croscopy in the conventional manner. 
Statistical Analysis.  Data were analyzed using one- or two-way 
analysis of variance (ANOVA) for the individual experiments. If 
significant  differences  were detected among group means, individual 
group means were then compared with positive controls so as to 
discern statistical differences  within data sets, using the Scheffe t 
test and the Fisher  protected  least significant  difference  (PLSD) com- 
parison tests. All values were expressed as mean  +  SEM, unless 
otherwise indicated.  Statistically,  significant  differences  were defined 
asp <0.05. For calculation of percent protection, negative control 
values were subtracted from both positive control values and from 
values of treated protective control groups. 
Results 
Analysis of CliO Cell-expressed Oligosaccharides,  Based on 
the average molecular weight of glycopeptides (3,750 for Con 
A-DSA unbound and 2,280 for DSA bound) and the amount 
used in in vivo experiments (186/,g/injection), the amount 
of each terminal structure can be calculated as shown in Table 
1.  The CHO-FT (fucosyl transferase-transfected ceils) cell 
glycopeptides used for in vivo experiments contained the com- 
position as described in Table 1.  The predominant species 
was SLX, with lesser amounts of sialyl LacNac, LacNAc, and 
Lewis  x, in descending order.  For each of the three intrave- 
nously injected doses (at 2, 2.5, and 3 h), the amounts (nmol) 
per injection of oligosaccharide are shown in Table 1.  As- 
suming distribution of the oligosaccharides into a total blood 
volume of 15 ml and excluding equilibration with the ex- 
travascular compartment, a single-dose oligosaccharide would 
yield a maximal blood concentration of 9 #M SLX. The other 
oligosaccharides would be at a much lower concentration. 
Ability  of Glycopeptide Fractions from  Fucosyl  Transferase- 
transfected and SLX-expressing Cells to Attenuate lgG Immune 
Complex-induced Lung Injury.  IgG immune complex-induced 
lung injury was quantitated at 4 h by vascular permeability 
(Fig.  1 A), hemorrhage (B), and by MPO content (C). Re- 
cent studies have indicated that this model of lung injury 
is E-selectin dependent (16). When the positive control group 
receiving intravenous injections of PBS (at 2.5, 3.0, and 3.5 h) 
was compared with the group similarly infused with 636 #g 
glycopeptide carbohydrate from CHO-V (vector-transfected) 
cells, no reduction in any of the three parameters was noted. 
Table  1.  Oligosaccharide  Structural Analysis of Concentrates Used for In Vivo Treatment 
Mass concentration 
Structure  Trivial name  (hexose in glycopeptide)  Amount injected* 
NeuNAco~2,3Gal~l,3(Fucoel,3)GlcNAc 
GalB1,4(Fucoll,3)GlcNAc 
NeuNAcc~2,3GalB1,4GlcNAc 
GalB1,4GIcNAc 
nmol//zg  nmol 
SLX  0.715  132.5 
Lewis  x  0.072  13.3 
sialyl LacNAc  0.402  74.5 
LacNAc  0.122  22.6 
* Approximately 185.3 #g hexose was administered per injection, and a total of three doses were given intravenously  at 2.5, 3.0 and 3.5 h. 
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Figure  1.  IgG immune complex-induced acute lung injury in rats 4 h 
after intrapulmonary deposition of IgG immune complexes. Injury was 
measured by the increase in vascular permeability (A) or hemorrhage (B). 
Lung content of MPO was also determined (C). The negative  permeability, 
hemorrhage, and MPO values in the negative controls (animals in which 
the intravenous injection of BSA was omitted) were: 0.16 _+ 0.01, 0.03 
+_ 0.001, and 0.11 •  0.01, respectively.  Values for positive reference con- 
trol groups (animals receiving PBS instead of an oligosaccharide  infusion) 
for permeability, hemorrhage, and MPO were: 0.68 + 0.03, 0.45 _+ 0.03, 
and .076 + 0.04, respectively.  CHO-V was the carbohydrate-rich product 
from CHO cells transfected  with vector alone (CHO-V cells) while CHO- 
FT was the carbohydrate-rich product from CHO cells transfected with 
the cDNA for c~(1,3/1,4) fucosyltransferase  (CHO-FT cells). Details are 
provided in the text. For each vertical bar, n  =  6. 
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Figure  2.  Protective  effects  of natural preparations (injected in equally 
divided doses intravenously at 2.5, 3.0, and 3.5 h) of SLX redudng sugar 
(SLX-OH) and the nonfucosylated oligosaccharide  (SLN-OH) in IgG im- 
mune complex-induced lung injury. Composition of material infused is 
described in Table 1 and in the first section of Results. Positive control 
values (PBS-infused  rats) for permeability (A), hemorrhage (B), and MPO 
(C) parameters were: 0.79 +_ 0.03, 0.25 _+ 0.01, and 0.63 +- 0.03, respec- 
tively. Details of treatment are provided in the text. For each vertical bar, 
n  ~  6. 
In contrast, in rats treated with 556/~g of glycopeptide car- 
bohydrate prepared from the cell line expressing SLX (CHO- 
FT), the permeability index was reduced by 60% (p <0.001), 
hemorrhage by 72%  (p <0.001),  and MPO content in lung 
fell by 40%  (p <0.001),  indicating  the protective effects of 
this reagent and a correlative reduction  in lung MPO con- 
tent.  Based on the reduction  of lung injury observed with 
natural carbohydrate containing SLX, synthetic preparations 
of SLX and related oligosaccharides were used in subsequent 
experiments. 
Reduction in IgG Immune Comflex-induced Lung Injury by 
Synthetically Generated SLX Oligosaccharides.  Synthetic SLX 
reducing  sugar  (SLX-OH)  or  the  nonfucosylated  control 
(SLN-OH) was administered intravenously at 2.5, 3.0,  and 
3.5 h after intrapulmonary deposition of immune complexes. x 
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Figure  3.  Ability  of tetrasaccharide  and pentasaccharide  (glycoside)  de- 
rivatives  of  SLX to reduce  lung vascular  injury  after  intrapulmonary  depo- 
sition of IgG immune  complexes.  Oligosaccharides  were  infused  intrave- 
nously in the indicated  doses at 2.5, 3.0, and 3.5 h after intrapulmonary 
deposition  of IgG immune  complexes.  Positive  control  values (PBS-treated 
rats) for permeability  (A), hemorrhage  (B), and MPO (C) parameters  were 
0.94 + 0.01, 0.31 _+ 0.01, and 0.64 _+ 0.02, respectively,  and are shown 
by the stippled horizontal bar. Details of treatment are provided for in 
the text. For each data point, n = 6. 
200/~g was injected at each of the three time points. Mea- 
surements of lung vascular injury were made at 4 h together 
with lung content of MPO. All comparisons were made to 
animals that had been treated intravenously with PBS instead 
of an oligosaccharide. These reference-positive control values 
(PBS), expressed as mean  _+ SEM, are shown in the bars in 
Fig. 2, A-C. When compared with results obtained in posi- 
tive control animals that had been treated with PBS, treat- 
ment of rats with SLN-OH showed no alteration in vascular 
permeability value (Fig.  2, A), no decrease in hemorrhage 
(B), and no decrement in lung content of MPO (C). In con- 
trast,  treatment with similar amounts of SLX-OH caused 
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modest reductions in permeability (20%, p  =  0.004), hemor- 
rhage (21%, p is not significant), and in MPO content (27%, 
p  =  0.005). 
Also examined were tetra- and pentasaccharide glycosides 
of SLX using a range of doses (50-500 #g) with intravenous 
injections of the indicated amounts at 2.5, 3.0,  and 3.5 h. 
Reference-positive controls received 200/~g SLN-OH intra- 
venously as the interventional agent; the values for these groups 
are shown by the horizontal bars (mean +  S.E.M.) indicated 
in each of the panels (Fig.  3). At all concentrations of SLX 
preparations used, there were significant reductions in lung 
injury as reflected by diminished vascular permeability. Over 
the dose range of 50, 100, 200, and 300/~g (injected in equal 
doses at each of the three time intervals indicated), treatment 
with the SLX-tetrasaccharide preparation reduced injury (as 
measured by permeability change) by 24% (p <0.001), 45% 
(p <0.001),  51%  (p <0.001),  and 53%  ~  <0.001),  respec- 
tively (Fig. 3 A). In the case of the SLX-pentasaccharide prep- 
aration, the reductions in permeability were 22% (p <0.001), 
28%  (p <0.001),  36%  (p <0.001),  and 50%  (p <0.001), 
respectively.  At the 100- and 200-/~g doses,  the SLX-tetra- 
saccharide was significantly more protective than the SLX- 
pentasaccharide (p  =  0.02 and 0.045,  respectively). When 
the effects of these oligosaccharides on hemorrhage were evalu- 
ated, only treatment with the two highest doses of tetrasac- 
charide  and  pentasaccharide  SLX  preparations  produced 
statistically significant protection. For the SLX-tetrasaccharide 
at the doses of 200 and 300/~g,  injury was reduced 33% 
=  0.004) and 56% (p <0.001), respectively; for the SLX- 
pentasaccharide, at the same doses,  injury was 33%  (p  = 
0.011) and 52% (p  =  0.001),  respectively (Fig.  3 B). With 
respect to the effects of the oligosaccharides on lung MPO 
content after deposition of IgG immune complexes, treat- 
ment with 50 #g of either the SLX-tetra- or pentasaccha- 
rides (at 2.5, 3.0, and 3.5 h) did not significantly reduce MPO 
content, but at the 100-, 200-, and 300-#g doses of the SLX- 
tetrasaccharide, reductions in MPO content were 21% (p  = 
0.01), 30% ~  =  0.004), and 36% (p =  0.003), respectively, 
while treatment with the SLX-pentasaccharide preparation 
reduced MPO content by 11% (p = 0.048), 38% (p = 0.002), 
and 34% (p  =  0.004), respectively. At any treatment when 
the SLX-penta- and tetrasaccharides were compared with each 
other there were no significant differences in MPO content. 
Thus, the protective effects of the tetra- and pentasaccharide 
preparations in the IgG immune complex model of lung in- 
jury are dose dependent and roughly correlate with reduc- 
tions in lung content of MPO. 
Morphological Correlates  of OligosaccMride-induced  Lung Pro- 
tection.  The features oflgG1 immune complex-induced acute 
lung injury 4 h after immune complex deposition in lungs 
are shown in Fig.  4 A,  in which tissue was derived from 
a positive control treated intravenously with 200/~g SLN- 
OH at 2.5, 3.0, and 3.5 h. There was extensive intraalveolar 
hemorrhage,  and  the  venules  and  capillaries  contained 
numerous neutrophils, many of which were in direct contact 
with the endothelial surfaces (arrows). In animals treated with 
200/zg SLX-tetrasaccharide at the same intervals of time, 
there was marked suppression of hemorrhage and, of the tel- Figure 4.  IgG immune  complex-induced  alveolitis at 4 h. In A, from an animal treated  with 200/zg SLN-OH at 2.5, 3.0, and 3.5 h, there was 
extensive  intnalveolar  hemorrhage.  Within the venules  and capillaries  many  neutrophils  were  in direct  contact  with the vascular  endothelium  (arrows). 
In animals treated  with 200/~g SLX-tetrasaccharide  using the same  protocol,  little alveolar  hemorrhage  developed  and, of the intravascular  neutrophils 
present, few were in contact with the endothelium  (arrows). (Toluidine  blue-stained sections, x 115.) 
atively few neutrophils that were present within the vascular 
compartment, they were within the vascular lumens and rarely 
in direct contact with the endothelial surfaces (Fig. 4 B, arrows). 
Inability of  SLX-OH to Protect  against IgA Immune Complex- 
induced Lung Injury.  The reducing sugar form of SLX (SLX- 
OH), which was protective in IgG immune complex-induced 
injury (Fig.  2), was also used in the IgA immune complex 
model of lung injury. In this model neutrophil recruitment 
is not involved in the injury-inducing events in lung (22) and 
E-selectin is not required for development of lung damage 
(25). Injury in this model appears due to generation of toxic 
oxygen and t-arginine-derived products from lung macro- 
phages (25, 26). As in the case of the IgG immune complex 
model of injury (Fig.  1). PBS,  SLN, or SLX-OH were in- 
fused intravenously at 2.5,  3.0,  and 3.5 h  after deposition 
of IgA immune complexes. The composition of the infused 
material is described in Table 1 and above. Permeability and 
hemorrhage parameters increased by two- to threefold when 
positive controls (treated with PBS) were compared with nega- 
tive controls (animals receiving an airway instillation of IgA 
antibody but no DNP-BSA intravenously [Fig.  5]),  When 
positive control animals were treated intravenously with ei- 
ther SLN or SLX-OH at 2.5, 3.0, and 3.5 h, there was no 
reduction in the intensity of injury, measured either by per- 
meability change (Fig. 5 A) or hemorrhage (B). As indicated 
above,  this is in contrast to  the protective effects of these 
oligosaccharides in lung injury induced by intrapulmonary 
deposition of IgG immune complexes (Fig.  2).  MPO data 
are not shown since, in this model, few neutrophils accumu- 
late in lung and neutrophil depletion is not protective (26). 
Discussion 
There is increasing evidence for the role of selectins in the 
inflammatory  response. The in vitro use of  perfusion chambers 
that permit visual observations of neutrophil-adhesive inter- 
actions to selectin-bearing surfaces under conditions of shear 
stress  has led to  the hypothesis that interactions of P- or 
E-selectins with "counter-receptors" on neutrophils can re- 
sult in the initial rolling of leukocytes along a selectin-bearing 
surface (12,  13). This rolling is thought to be due to inter- 
mittent adhesive interactions between neutrophils and en- 
dothelial cells, resembling the earliest events in vivo in the 
acute inflammatory reaction during which time neutrophils 
convert from a rapid luminar flow to a "margination;' which 
is manifested as a rolling along the endothelium at a rate that 
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Figure 5.  Protective effects of natural preparations (200/~g injected in- 
travenously at 2.5, 3.0, and 3.5 h) of SLX-OH and the nonfucosylated 
SLN-OH in IgA immune complex-induced acute lung injury. Composi- 
tion of material infused is described in Table I and in the first section of 
Results. Negative and positive (PBS-treated) control wlues for permeability 
were 0.16 •  0.01 and 0.37  •  0.02, respectively. Comparison values for 
hemorrhage were 0.04  •  0.001 and 0.15  •  0.01, respectively. For each 
vertical bar, n  =  4. 
is much slower than that of cells being carried along by the 
luminal flow of blood. After the selectin-dependent  rolling 
phenomenon, it appears that the next sequence of adhesion- 
promoting interactions  involves 152 integrins of the neutro- 
phil and the counter-receptors on the endothelial cell, ICAM-1 
or -2 (15). Integrin-mediated adhesion appears to result in 
a tight adhesive interaction between neurophils and the en- 
dothelium, producing a cessation of rolling, a flattening and 
spreading on the endothelium of the neutrophil, and the move- 
ment beyond the endothelial barrier (through intercellular 
junctions) of the neutrophil (13). 
The in vivo evidence documenting the requisite  role of 
selectins in the inflammatory response is limited. There is 
experimental evidence suggesting that in animals E-selectin 
may be a homing molecule for a subclass of T cells (27). Ex- 
pression of endothelial E-selectin (using immunohistochem- 
ical analysis) has been demonstrated in human skin obtained 
from patients with contact hypersensitivity reactions (28, 29), 
in the vasculature of synovial tissues in patients  with rheu- 
matoid arthritis (30) and in multiple vascular beds of baboons 
infused with LPS (31, 32), providing indirect evidence for 
the possible involvement of E-selectin in these inflammatory 
conditions. In IgG immune complex-induced dermal and lung 
vasculitis, vascular expression of rat E-selectin (ELAM-1) has 
been shown immunohistochemically, and protective effects 
(which have been associated with greatly reduced neutrophil 
influx)  have been obtained by blocking of E-selectin with 
F(ab')2 preparations  of anti-E-selectin  (16). Blocking  of 
629  Mulligan et al. 
I.-selectin by the use of antibody (33) or by the use of a 
L-selectin-Ig chimeric molecule (34) has reduced the influx 
of neutrophils into the peritoneal  cavity of mice. Sialidase 
treatment of animals or the use of carbohydrates that prevent 
adhesive interactions  between T cells and high endothelial 
cells of lymph nodes also interferes  with the recirculation (from 
blood to tissues and ultimately back to the blood compart- 
ment) of T cells (35), suggesting that r-selectin may also be 
an important participant in inflammatory responses featuring 
the participation  of neutrophils,  T  cells, or monocytes. 
Compelling evidence for the importance of E-selectin and 
P-selectin interaction with their carbohydrate ligand, SLX, 
on neutrophils comes from the recent description  of a new 
leukocyte adhesion deficiency stemming from the absence of 
SLX on patients' neutrophils (36). Although not as severe 
as the classic leukocyte adhesion deficiency, which features 
a defect in the neutrophil CD18 integrins, the pronounced 
deficiency exhibited by SLX-deficient individuals results in 
recurrent severe  infections and high neutrophil counts in blood. 
Thus, it is reasonable to assume that disruption of the E- and 
Poselectin interactions  with SLX-containing ligands on the 
neutrophil will also prevent neutrophil migration into tissues 
in inflammatory conditions and prevent resultant neutrophil- 
mediated damage. 
In this study, we have addressed the potential for soluble 
forms of the E-selectin ligand, SLX, to inhibit an E-selectin- 
dependent model of inflammation, the acute lung injury after 
the acute inflammatory vascular injury after deposition of IgG 
immune complexes. In this model of injury, engagement and 
activation of neutrophils is crucial. Neutrophil migration into 
the alveolar compartment containing IgG immune complex 
deposits results in protease release and generation of nitrogen- 
and oxygen-centered free radicals. Pulmonary macrophages 
also contribute to the outcome of injury of vascular endothelial 
and alveolar epithelial cells by their production of oxidants 
and their release of cytokines that appear to upregulate en- 
dothelial  adhesion molecules (17, 37, 38).  On the basis of 
the data in the current report, the infusion of natural N-linked 
oligosaccharides containing SLX or synthetic derivatives of 
SLX causes significant reduction of lung injury and a corre- 
sponding reduction in neutrophil accumulation in lung tissue. 
The incomplete protection by SLX compounds against this 
type of injury could be due to a variety of factors, including 
SLX oligosaccharide blood levels that are insufhcient to com- 
pete totally with the in vivo presentation of SLX on the neu- 
trophil. Other explanations could be the rapid engagement 
of the/82 integrin/ICAM-1, -2 pathway,  or injury due to 
nonneutrophil-dependent mechanisms. With respect to the 
last possibility, the IgA immune complex model of acute lung 
injury is informative. In this model of lung injury, it is known 
that little neutrophil recruitment occurs; pulmonary macro- 
phages appear to be the key effector cells in events leading 
to pulmonary injury. In this model, little vascular expression 
of E-selectin is found and blocking antibody to E-selectin 
has no protective effects (in striking contrast to findings in 
the IgG immune complex model) (25). Similarly, as presented 
in Fig. 5, SLX oligosaccharides also have no protective effects 
in this model. The ability of SLX oligosaccharides to  protect  against 
neutrophil-mediated acute lung injury, as documented in this 
report, suggests that the development of SLX-bearing con- 
jugates may be effective antiinflammatory approaches.  Crit- 
ical needs  at present are access to more effective glycocon- 
jugates with prolonged half-lives in the circulation, a clearer 
definition of the interactions between oligosaccharides  and 
selectins, and more information regarding inflammatory  con- 
ditions in which selectins  are playing an important role in 
the development of the inflammatory response. 
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